nice post from sello from another board: sello Member

New Post Public Reply Private Reply Replies (0) Message Board
truebeliever
298
nice post from sello from another board:

sello Member Level Sunday, 12/08/19 08:11:33 AM
Re: None 0
Post # of 38272

I knew that PCT had something special here but after spending the last couple of days researching Candida Auris I realize just how vital this system is for an epidemic that is raising alarm around the globe.

This strain of fungus is like nothing ever seen before and though it has been purposely kept under the radar until recently to avoid panic, the CDC has put a priority focus on identification and isolation in the last couple of years.

The mortality rate for those affected is around 50%. In April of this year 539 cases were identified in the US. At the end of September there were 888 nationwide. At the current rate of growth it has been estimated that if no new anti-fungal and antibiotic drugs are created to treat this infection. and the others resistant infections, they will surpass cancer in death toll by the year 2050.

The reason PCT is targeting, and getting into the top New York hospitals is because New York is the epicenter of the US cases with 380 of the current cases acquired in New York hospitals. London has been hit hard as well which explains the recent installation there.

One of the aspects of Candida Auris and it's high resistance to both anti-fungal and standard disinfectants is the bio film that protects it. Right now the only approved environmental treatments approved by the CDC are chlorine based products.

So bleach does kill this as chlorine is it's base. The problem is that this thing is not contained to standard surface contamination so standard disinfecting protocol using bleach based products requiring human application is not sufficient. These spores are present in every part of a contaminated room, ceilings, fixtures, even electrical outlets. One hospital that had an outbreak of 72 cases in London had to close down the entire ICU and remove ceilings and walls before finally getting rid of the stuff.

This is where Hypoclorous acid, also having clorine as it's base and also approved as an effective treatment for C auris, comes into play. You can't use bleach through an electrostatic application because, unlike hypoclorous, it is toxic. This makes it nearly impossible to fully disinfect a room with bleach.

PCT has set themselves apart from the competition in the hypoclorous acid sector by offering a complete package of onsite production, electrostatic application, protocol software, and most important the patented tracking software as product life has always been one of the biggest concerns with the use of HOCL.

This is ground floor folks. I think the next step is a bridge to profitability with contract based lines of credit after that and explosive growth in the coming years.


PCTL!!

PCT Ltd. (PCTL) Stock Research Links

PCTL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Microfluidics Market Growth: Insights and Future Trends

Updated Category News Views 112

Microfluidics Market Overview The global microfluidics market, valued at approximately USD 21.36 billion, is set for impressive growth. Predictions suggest it will reach about USD 32.67 billion by the end of 2029. This significant expansion is a clear indicator of the transformation occurring within diagnostics, life sciences, and pharmaceutical research. Driving Forces...

Continue Reading
How a $1000 Investment in Primerica Can Grow Over Time

Updated Category News Views 333

The Incredible Growth of Primerica Primerica (NYSE: PRI) has truly left a mark in the financial sector, showcasing remarkable performance over the last decade. With an annualized return of 17.97%, it has outperformed the market by 7.08%, demonstrating its strong foundational growth and investment appeal. As of now, Primerica holds a market capitalization of $9.18 billion,...

Continue Reading
Illumina Joins Forces with MyOme: A Game Changer in Healthcare

Updated Category News Views 115

Illumina and MyOme Collaboration Overview Illumina has recently entered into a significant collaboration deal with MyOme, a company specializing in genomic analysis. This partnership isn't just a strategic investment; it's an aerospace-like synergy aimed at transforming how healthcare operates in the United States. With a bold vision, the duo is set to explore innovative...

Continue Reading
BlackSky Technology Secures Major Contract Boosting Stock Appeal

Updated Category News Views 117

BlackSky Technology Gains Momentum After Major Contract Win BlackSky Technology Inc (BKSY) has seen its shares trade higher recently thanks to the remarkable announcement of a five-year contract with the U.S. National Geospatial-Intelligence Agency (NGA). This contract, valued at up to $290 million, will enable BlackSky to leverage its advanced satellite monitoring...

Continue Reading
BioXcel Therapeutics to Showcase Innovations at Conference

Updated Category News Views 255

BioXcel Therapeutics: AI in Medicine BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is making waves in the biopharmaceutical sector using artificial intelligence (AI) to forge new paths in neuroscience medication. The CEO, Vimal Mehta, Ph.D., will take the stage at the highly regarded Canaccord Genuity 45th Annual Growth Conference. This pivotal event will take place in...

Continue Reading